Ocrelizumab for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

So far, Altmetric has seen 3 public wall posts from 3 users.

Ocena skuteczności okrelizumabu, względem innch leków, u chorych ze stwardnieniem rozsianym #CochranePolska #badanianaukowe

What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This The Cochrane Library #systematicreview evaluates…

💊 What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This #systematicreview evaluates the evidence from 4…